Survivin is an ideal target for discovery of anticancer drugs because it is expressed only in cancers but not adult human tissues.

Antibiotic gel formulations, including low concentrations of two antibiotics, are capable of killing root canal pathogens without harming the stem cells inside the root canal.

Sphingosine 1-phospate metabolizing enzymes are involved in modulating cellular responses to a variety of viruses in human and veterinary applications. 

This novel composition comprising beta-lactam antibiotics and branched polyethylenimine (BPEI) restores the susceptibility of MRSA to beta-lactams.

Titanium dioxide nanoparticles are doped or co-doped with elements such as nitrogen to produce novel multifunctional nanoparticles that are capable of addressing the current need for biomaterials that have non-leaching and long-lasting antibacterial properties.

A proprietary high-throughput screening method to identify and characterize in-cell based assays compounds that inhibit FATP2 mediated fatty acid uptake.

Combination of Proton Pump Inhibitors (PPIs) Omeprazole and Lansoprazole in a buffered composition for 24-hour gastric pH control to treat a variety of acid-related disorders such as Barrett’s Esophagus, Gastroesophageal Reflux Disease, and others. 

This transformative initiative focuses on the development and clinical introduction of a first-in-class drug to safely and effectively treat early stage fatty liver disease.

This novel receptor composition redirects the cytotoxicity of T-lymphocytes towards the FLT3 receptor expressing acute myeloid leukemia (AML) cells by expressing a chimeric antigen receptor (CAR) with FLT3 ligand (FL) at the extracellular antigen-binding domain.

Novel nanoparticle formulation is designed to address the barrier deficit associated with chronic skin disorders such as atopic dermatitis.

Pioglitazone, currently approved for treatment of diabetes under the trade name Actos, is effective in delaying cyst growth in polycystic kidney disease (PKD). 

A scaling-up method for producing drug nanocrystals that combines the top-down and bottom-up approaches.

T cell interactions with specific receptors/ligands on lymphatic endothelium are necessary for the egress of T cells from peripheral lymph nodes into the circulation.

More details coming soon!

Metformin, a naturally-occurring biguanide, is an FDA-approved high-safety profile diabetes drug that has been used extensively for decades.

Researchers at the University of Kentucky have demonstrated that elevated fasting levels of neurotensin could be a potential target for treating obesity and insulin resistance. Additionally, high levels of neurotensin in non-obese patients doubles the risk of the development of obesity later in life, thus presenting a potential protective effect for neurotensin as a therapeutic target.

InnoBioPharma has developed several novel drug candidates (two in pre-clinical trials) that are particularly effective against aggressive cancers that lack effective drug therapy.

A molecule capable of specifically inhibiting the NF-κB pathway, a key target involved in a variety of cancers and other diseases.

An effective method of treatment for chronic and inflammatory pain by inhibiting selective adenylyl cyclases, especially adenylyl cyclase 1. Compounds may also prevent and/or reduce opioid dependence.

Fungal infections are known to develop resistance to commonly used azoles that are in use in the clinic today.  There remains a need for an effective and safe alternative to treating drug-resistant fungal strains in both humans and plants, and this technology addresses this critical point as an efficacious azole-based therapy which can treat drug resistant fungal infections.

Peptide-based therapeutic agents that inhibit the CAPN5 enzyme.

Novel inhibitors targeting 3C or 3CL virus proteases.

Cancers persist only when they evade the host’s immune system.  This novel cancer therapy resensitizes the host immune system to cancer epitopes through a novel method involving vaccination with a treated sample of the biopsied tumor.  Trials in canines have demonstrated efficacy.  Patents pending.

Wet age-related macular degeneration (AMD) is known to negatively affect aging populations. The disease can result in blindness and can lead to a severe decline in quality of life.

A substrate mediated delivery system for highly controlled local and sustained release of any hydrophobic or hydrophilic cargo.

Cancer treatments with minimal adverse events and improved efficacy are what every pharmaceutical/biotech company strives for in their R&D pipeline.

Therapeutic peptides to combat excessive inflammation and tissue damage in response to ischemia/reperfusion (IR).

Cell-specific non-toxic reagent for the treatment of hematological and other cancers. Data using micelles composed of peptide amphiphiles targeted using aptamers demonstrate efficacy against a wide range of human and canine cancers, as well as low toxicity in vivo, and 2-3x longer median survival.  Patents issued and pending.

A therapeutic vaccine for patients with recurrent prostate cancer that effectively destroys expressing tumor cells while leaving normal cells unharmed.

A collaboration between Kansas State University and Wichita State University has led to the development of protease inhibitors with improved pharmacokinetics (PK) and bioavailability using a prodrug approach of peptidyl aldehyde compounds.

More info coming soon!

This novel small molecule inhibits ARID3a and results in inhibition of IFNa levels, thereby having the potential for use in treatment of lupus and other immune/inflammatory diseases (e.g., rheumatoid arthritis, Sjogrens syndrome).

In humans, there are two nearly identical copies of the Survival Motor Neuron (SMN) gene, SMN1 and SMN2.  Loss of SMN1 in conjunction with skipping of SMN2 exon 7 in pre-mRNA splicing—which results in a truncated, unstable SMN—leads to spinal muscular atrophy. 

Combination treatment of Ig-GAD2 and stem cells to cure Type I Diabetes (TID).  Data demonstrate a functional cure in a mouse model for TID through restoration of immune tolerance coupled with regeneration of endothelial cells in the pancreatic islets. Patents issued and pending.

Azaindenoisoquinoline compounds that act as inhibitors of Top1, TDP1, and TDP2 for cancer treatment

TR3 Technology delivers a new generation of TNF superfamily TRAIL (TNF-related apoptosis-inducing ligand, designated TR3) directly to MUC16-expressing cancer cells.

More info coming soon!

Prostate Cancer (PC) is commonly treated with androgen deprivation therapy (ADT), but tumors may become resistant to androgen removal and are then categorized as Castration-Resistant PC (CRPC).

LoDos Theranostics has developed “first-in-class” nanoparticles called “Radio-Luminescent Nano Particles (RLNPs)” which will be injected into the tumor before a patient receives radiation treatment: The first product to endogenously deliver UV light to deep tumors.